Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.).

NCT02382900 is registered in ClinicalTrials.gov with Universidad Nacional Autonoma de Mexico as lead sponsor.

NCT NCT02382900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02382900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.).
Lead sponsor
Universidad Nacional Autonoma de Mexico
Phase
Phase 3
Overall status
Unknown status
Start date
February 28, 2015
Completion date
December 31, 2015
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human papilloma virus